Instrument Inactif

Communiqués Flexion Therapeutics, Inc.

Actions

FLXN

US33938J1060

Communiqués

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

FLEXION THERAPEUTICS INC : Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Triggering Events That Accelerate or Increase a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders, Changes in Control or Registrant, (form 8-K)	19/11/21	AQ
FLEXION THERAPEUTICS INC MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-Q)	12/11/21	AQ
FLEXION THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Flexion Therapeutics, Inc. - FLXN	12/10/21	BU
FLEXION THERAPEUTICS INC : Entry into a Material Definitive Agreement, Results of Operations and Financial Condition, Other Events, Financial Statements and Exhibits (form 8-K)	12/10/21	AQ
Flexion Therapeutics : Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	01/10/21	GL
Flexion Therapeutics to Present at the H.C. Wainwright 23rd Annual Global Investment Conference	08/09/21	GL
Flexion Therapeutics : to Present at the Wells Fargo 2021 Virtual Healthcare Conference	06/09/21	AQ
Flexion Therapeutics : Announces Inclusion of ZILRETTA in American Academy of Orthopaedic Surgeons (AAOS) Clinical Practice Guidelines for the Management of Osteoarthritis of the Knee	03/09/21	AQ
Flexion Therapeutics to Present at the Wells Fargo 2021 Virtual Healthcare Conference	03/09/21	GL
Flexion Therapeutics : Announces Inclusion of ZILRETTA® in American Academy of Orthopaedic Surgeons (AAOS) Clinical Practice Guidelines for the Management of Osteoarthritis of the Knee	02/09/21	AQ
Flexion Therapeutics : Announces Expansion of Phase 1b Trial Investigating FX301 for the Management of Post-Operative Pain	25/08/21	AQ
Flexion Therapeutics : Announces Publication of Results from Phase 2 Pharmacokinetics (PK) and Safety Study of ZILRETTA® in Shoulder Osteoarthritis (OA)	09/08/21	AQ
Flexion Therapeutics : Q2 2021 Commercial Metrics Overview - August 4, 2021	05/08/21	PU
Flexion Therapeutics : Reports Second-Quarter 2021 Financial Results and Recent Business Highlights (Form 8-K)	04/08/21	PU
Flexion Therapeutics: Q2 Earnings Snapshot	04/08/21	AQ
FLEXION THERAPEUTICS : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-Q)	04/08/21	AQ
Flexion Therapeutics : Reports Second-Quarter 2021 Financial Results and Recent Business Highlights	04/08/21	AQ
Flexion Therapeutics : to Report Second-Quarter 2021 Financial Results on August 4, 2021	29/07/21	AQ
FLEXION THERAPEUTICS INC : Change in Directors or Principal Officers (form 8-K)	12/07/21	AQ
Flexion Therapeutics Announces Appointment of Utpal Koppikar to its Board of Directors	12/07/21	GL

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Communiqués Flexion Therapeutics, Inc.

Actions

FLXN

US33938J1060

Communiqués

Filtres